A 58-year-old man with metastatic non-small-cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion mutation is referred for targeted therapy. Which is the preferred first-line treatment?

Explanation

## EGFR Mutation–Driven NSCLC: First-Line Targeted Therapy **Key Point:** Afatinib, a second-generation irreversible EGFR tyrosine kinase inhibitor (TKI), is the preferred first-line treatment for EGFR-mutant NSCLC (exon 19 deletions or L858R mutations). It demonstrates superior progression-free survival (PFS) compared to first-generation EGFR TKIs. **High-Yield:** The LUX-Lung 3 and LUX-Lung 6 trials established afatinib as superior to chemotherapy in EGFR-mutant NSCLC, with median PFS of 11–13 months versus 6–7 months with chemotherapy. ### Mechanism of Action Afatinib is an **irreversible pan-HER inhibitor** that covalently binds to the ATP-binding pocket of EGFR, HER2, and HER4. This irreversible mechanism provides sustained target inhibition and overcomes some resistance mechanisms seen with reversible first-generation TKIs (erlotinib, gefitinib). ### Comparative Efficacy: First vs. Second-Generation EGFR TKIs | Parameter | Erlotinib | Gefitinib | Afatinib | | --- | --- | --- | --- | | **Mechanism** | Reversible | Reversible | Irreversible (pan-HER) | | **Median PFS** | 9–10 months | 9–10 months | 11–13 months | | **Median OS** | Similar | Similar | Superior in some trials | | **Resistance** | T790M common | T790M common | Lower T790M emergence | | **Toxicity** | Moderate | Moderate | Higher diarrhea, rash | | **Role** | Second-line (if T790M−) | Second-line (if T790M−) | **First-line standard** | **Clinical Pearl:** Afatinib-induced diarrhea is dose-limiting and requires proactive management (antidiarrheals, dose reduction). Despite higher toxicity, superior PFS justifies its use as first-line in EGFR-mutant disease. ### Why Not First-Generation TKIs? Erlotinib and gefitinib are reversible inhibitors with lower binding affinity and shorter target occupancy. While effective, they are now reserved for: - Second-line therapy in EGFR-mutant NSCLC (if afatinib not tolerated) - Maintenance therapy after chemotherapy - Resource-limited settings where afatinib is unavailable ### Why Not Chemotherapy? Cisplatin + pemetrexed is standard for EGFR wild-type NSCLC. In EGFR-mutant disease, targeted TKI therapy is superior, with better response rates, PFS, and tolerability compared to chemotherapy. **Mnemonic:** **AFATINIB = Affinity + Irreversible** — Afatinib's **A**ffinity for multiple HER receptors and **I**rreversible binding make it the **F**irst-line choice in EGFR-mutant NSCLC.